Ingenuity Systems, the leading provider of information solutions for life science researchers, announced the signing of a four year agreement with Boehringer Ingelheim for Ingenuity Pathway Analysis (IPA).

IPA will be used throughout the Boehringer Ingelheim research and development organization to unlock novel insights from experimental data and as a general tool for biological search and exploration.

The agreement provides global access for Boehringer Ingelheim research scientists to access to the recently released IPA 6, which includes new biological and chemical content, in addition to Path Designer, an award-winning set of tools that more clearly communicates information about networks and pathways.

"We are pleased at this opportunity to become a strategic partner in Boehringer Ingelheim's research and development efforts," stated Jake Leschly, CEO, Ingenuity Systems.

Ingenuity Pathways Analysis is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signalling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.

Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity's products and services have one common goal -- to help life science researchers generate maximum value from all types of biological and chemical knowledge.